Cancer Center Director: Tyler J. Curiel, M.D., M.P.H. 7979 Wurzbach Road Mail Code 8026 Urschel Tower, Room U627 San Antonio, TX 78229 Tel: (210) 567-2711 Fax: (210) 567-2709 Visit Website Clinical Trials at this Center

The San Antonio Cancer Institute (SACI) was renamed to the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio (UTHSCSA). The CTRC at UTHSCSA is a patient care, research and educational center of the Health Science Center School of Medicine.

The Cancer Therapy & Research Center (CTRC), located in San Antonio, Texas, merged with and became a center of The University of Texas Health Science Center at San Antonio in December 2007. Before the merger, the two institutions were partners in the San Antonio Cancer Institute, one of the three National Cancer Institute (NCI)–designated Cancer Centers in Texas.

Tyler J. Curiel, M.D., M.P.H., an internationally known medical oncologist and cancer researcher, has been named director of the cancer center. Frank Giles, M.D., M.B., FRCPI, FRCPath, has been promoted to deputy director of the cancer center and continues as director of the CTRC Institute for Drug Development (IDD) and Experimental and Developmental Therapeutics program.

The CTRC at UTHSCSA serves more than 4.4 million people in the high–growth corridor of South and Central Texas, including San Antonio, Austin, Laredo and the Rio Grande Valley. It handles more than 120,000 patient visits each year.

The mission of the CTRC at the UT Health Science Center is to promote interdisciplinary research in cancer–related areas of basic science, clinical research, and cancer prevention and control, and to foster the application of the results of that research in the community setting, especially in the South Texas community.

The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical research studies program in the world. In a Phase I research study, a new agent for cancer is tested in human patients for the first time. Fifteen of the cancer drugs most recently approved by the U.S. Food and Drug Administration underwent development or testing at the IDD.